-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, MSOiMeYUrscqe7/eicC509uTPgJ0qUutw5q7drcp1hGGa6QaLAlJJ2322K1epEgK tm2GZ1/B62/usej4uxc0NQ== 0000950116-00-000328.txt : 20000221 0000950116-00-000328.hdr.sgml : 20000221 ACCESSION NUMBER: 0000950116-00-000328 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20000218 GROUP MEMBERS: FREDERICK R. ADLER INTANGIBLE ASSET MANAGMENT TRUST GROUP MEMBERS: IMPAX LABORATORIES INC GROUP MEMBERS: SUSAN R. CHAPMAN, TRUSTEE SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IMPAX LABORATORIES INC CENTRAL INDEX KEY: 0001003642 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 650403311 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-48867 FILM NUMBER: 549457 BUSINESS ADDRESS: STREET 1: CASTOR & KENSINGTON AVES CITY: PHILADELPHIA STATE: PA ZIP: 19124-5694 BUSINESS PHONE: 2152892220 MAIL ADDRESS: STREET 1: CASTOR & KENSINGTON AVENUES CITY: PHILADELPHIA STATE: PA ZIP: 19124-5694 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL PHARMACEUTICAL CORP \DE\ DATE OF NAME CHANGE: 19951117 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: IMPAX LABORATORIES INC CENTRAL INDEX KEY: 0001003642 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 650403311 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: CASTOR & KENSINGTON AVES CITY: PHILADELPHIA STATE: PA ZIP: 19124-5694 BUSINESS PHONE: 2152892220 MAIL ADDRESS: STREET 1: CASTOR & KENSINGTON AVENUES CITY: PHILADELPHIA STATE: PA ZIP: 19124-5694 FORMER COMPANY: FORMER CONFORMED NAME: GLOBAL PHARMACEUTICAL CORP \DE\ DATE OF NAME CHANGE: 19951117 SC 13G/A 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Impax Laboratories, Inc. ----------------------------------------------------- (Name of Issuer) Common Stock, $.01 par value ----------------------------------------------------- (Title of Class of Securities) 45256B101 ------------------------------------------------------ (CUSIP Number) December 14, 1999 ----------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is being filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 45256B101 13G Page 2 of 7 Pages - ------------------------------------------------------------------------------ 1 NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY). Frederick R. Adler Intangible Asset Management Trust - ------------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [x] (b) [ ] - ------------------------------------------------------------------------------ 3 SEC USE ONLY - ------------------------------------------------------------------------------ 4 CITIZENSHIP OR PLACE OF ORGANIZATION New York - ------------------------------------------------------------------------------ 5 SOLE VOTING POWER 575,350 shares - See Item 4(a) NUMBER OF SHARES -------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER OWNED BY 0 EACH REPORTING PERSON -------------------------------------------------- WITH 7 SOLE DISPOSITIVE POWER 575,350 shares - See Item 4(a) -------------------------------------------------- 8 SHARED DISPOSITIVE POWER 0 - ------------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 575,350 - See Item 4(a) - ------------------------------------------------------------------------------ 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* - ------------------------------------------------------------------------------ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.3% - See Item 4(a) - ------------------------------------------------------------------------------ 12 TYPE OF REPORTING PERSON* OO - ------------------------------------------------------------------------------ *SEE INSTRUCTIONS BEFORE FILLING OUT CUSIP No. 45256B101 13G Page 3 of 7 Pages - ------------------------------------------------------------------------------ 1 NAMES OF REPORTING PERSONS. I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY). Susan R. Chapman, Trustee - ------------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [x] (b) [ ] - ------------------------------------------------------------------------------ 3 SEC USE ONLY - ------------------------------------------------------------------------------ 4 CITIZENSHIP OR PLACE OF ORGANIZATION United States - ------------------------------------------------------------------------------ 5 SOLE VOTING POWER 637,696 shares - See Item 4(a) NUMBER OF SHARES -------------------------------------------------- BENEFICIALLY 6 SHARED VOTING POWER OWNED BY 0 EACH REPORTING PERSON -------------------------------------------------- WITH 7 SOLE DISPOSITIVE POWER 637,696 shares - See Item 4(a) -------------------------------------------------- 8 SHARED DISPOSITIVE POWER 0 - ------------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 637,696 - See Item 4(a) - ------------------------------------------------------------------------------ 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* - ------------------------------------------------------------------------------ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 2.67% - See Item 4(a) - ------------------------------------------------------------------------------ 12 TYPE OF REPORTING PERSON* IN - ------------------------------------------------------------------------------ *SEE INSTRUCTIONS BEFORE FILLING OUT CUSIP No. 45256B101 13G Page 4 of 7 Pages Item 1. (a) Name of Issuer: Impax Laboratories, Inc. (b) Address of Issuer's Principal Executive Offices: 30831 Huntwood Avenue Hayward, CA 94544 Item 2. (a) Name of Person Filing: The Frederick R. Adler Intangible Asset Management Trust (the "Trust") and Susan R. Chapman, Trustee. (b) Address of Principal Business Office: c/o Susan R. Chapman, Trustee 175 East 64th Street New York, New York 10021 (c) Citizenship: The Trust is governed by the laws of the State of Florida, even though Florida is not the situs of the Trust. Susan R. Chapman is a citizen of the United States. (d) Title of Class of Securities: Common Stock, par value $.01 (e) CUSIP Number: 45256B101 Item 3. Not Applicable Item 4. Ownership. (a) Amount beneficially owned: The 575,350 shares of Common Stock beneficially owned by the Trust includes 246,914 shares of Common Stock which were issued upon the conversion of 5,000 shares of Series A Convertible Preferred Stock. The 637,696 shares of Common Stock beneficially owned by Ms. Chapman includes the 575,350 shares owned by the Trust, of which Ms. Chapman serves as Trustee. The additional 62,346 shares beneficially owned by Ms. Chapman includes 50,000 shares of Common Stock held by Longview Partners, L.P., of which Ms. Chapman is the General Partner, and 12,346 shares of Common Stock which were issued upon the conversion of 250 shares of Series B Convertible Preferred Stock owned of record by Philip R. Chapman, spouse of Ms. Chapman. Ms. Chapman disclaims beneficial ownership of the 637,696 shares for purposes of Section 16 or for any other purpose. (b) Percent of class: See Item 11 of the cover page attached hereto and Item 4(a) above. CUSIP No. 45256B101 13G Page 5 of 7 Pages (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: See Item 5 of the cover page attached hereto and Item 4(a) above. (ii) Shared power to vote or to direct the vote: See Item 6 of the cover page attached hereto. (iii) Sole power to dispose or to direct the disposition of: See Item 7 of the cover page attached hereto and Item 4(a) above. (iv) Shared power to dispose or to direct the disposition of: See Item 8 of the cover page attached hereto. Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [x]. (The decrease in percentage of beneficial ownership of the reporting person is a result of the merger of Global Pharmaceutical Corporation and Impax Pharmaceuticals, Inc. on December 14, 1999, pursuant to which the shareholders of Impax Pharmaceuticals, Inc. were issued approximately 16,904,114 shares of common stock of the combined company and 170,000 shares of preferred stock of the combined company, initially convertible into 11,341,651 shares of common stock of the combined company. Global Pharmaceutical Corporation was the legal survivor of the merger, and in connection therewith changed its name to Impax Laboratories, Inc.) Item 6. Ownership of More Than Five Percent on Behalf of Another Person. Not Applicable Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8. Identification and Classification of Members of the Group. Not Applicable Item 9. Notice of Dissolution of Group. Not Applicable Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. CUSIP No. 45256B101 13G Page 6 of 7 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Frederick R. Adler Intangible Date: February 18, 2000 Asset Management Trust By: /s/ Susan R. Chapman ------------------------------ Susan R. Chapman, on behalf of the Trust and as Trustee CUSIP No. 45256B101 13G Page 7 of 7 Pages JOINT FILING AGREEMENT Pursuant to and in accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree to jointly file this Amendment to Schedule 13G dated February 18, 2000 and any amendments thereto with respect to the beneficial ownership by each of the undersigned of shares of common stock of Impax Laboratories, Inc. Such joint filings may be executed by one or more of us on behalf of each of the undersigned. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original. Executed this 18th day of February, 2000. FREDERICK R. ADLER INTANGIBLE ASSET MANAGEMENT TRUST /s/ Susan R. Chapman ------------------------------------ Susan R. Chapman, on behalf of the Trust FREDERICK R. ADLER INTANGIBLE ASSET MANAGEMENT TRUST /s/ Susan R. Chapman, Trustee ------------------------------------ Susan R. Chapman, Trustee -----END PRIVACY-ENHANCED MESSAGE-----